XML 60 R2.htm IDEA: XBRL DOCUMENT v3.26.1
Pay vs Performance Disclosure - USD ($)
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Pay vs Performance Disclosure          
Pay vs Performance Disclosure, Table
Year-end value of $100 invested on 3/26/2021 in:
Year
Summary Comp. Table Total for John Kao(1)
($)
Comp. Actually Paid to John Kao (2)
($)
Average Summary Comp. Table Total for Non-PEO NEOs (3)
($)
Average Comp. Actually Paid to Non-PEO NEOs (4)
($)
ALHC Total Shareholder Return(5)
($)
NASDAQ Health Care Index Total Shareholder Return(6)
($)
Net Income
(in millions) (7)
($)
Adj. EBITDA
(in millions) (8)
($)
(a)
(b)(c)(d)(e)(f)(g)
       (h)
(i)
202511,278,56952,285,3093,567,18111,082,021114.10100.74(1.00)109.90
20246,369,16525,237,0772,715,0027,114,60464.9982.17(128.07)1.34
2023
14,296,476(2,674,822)4,760,4491,769,823
49.74
82.87
(148.17)(35.3)
202234,070,59225,813,2787,327,4705,661,77967.9477.79(149.6)(26.7)
202145,998,85137,304,18710,891,54610,053,24481.2297.76(195.3)(33.1)
        
Company Selected Measure Name Adjusted EBITDA        
Named Executive Officers, Footnote The dollar amounts reported in column (b) are the amounts of total compensation reported for Mr. Kao (the “PEO”) for each corresponding year in the “Total” column of the Summary Compensation Table (“SCT”) in this proxy statement. The dollar amounts reported in column (d) are the average of the amounts of total compensation reported for the non-PEO NEOs for each corresponding year in the “Total” column of the SCT. For 2025, the Non-PEO NEOs were Dawn Maroney, James M. Head, Thomas Freeman, Hyong (Ken) Kim, M.D. and Christopher Joyce. For 2024, the Non-PEO NEOs were Dawn Maroney, Thomas Freeman, Hyong (Ken) Kim, M.D. and Andreas Wagner. For 2023, the Non-PEO NEOs were Dawn Maroney, Thomas Freeman, Hakan Kardes and Hyong (Ken) Kim, M.D. For 2022, the Non-PEO NEOs were Thomas Freeman, Dawn Maroney, Dinesh Kumar and Richard Cross. For 2021, the Non-PEO NEOs were Thomas Freeman, Dawn Maroney, Dinesh Kumar and Rajesh Shrestha.        
Peer Group Issuers, Footnote The peer group used for this purpose is the following published industry index: NASDAQ Healthcare Index.        
PEO Total Compensation Amount $ 11,278,569 $ 6,369,165 $ 14,296,476 $ 34,070,592 $ 45,998,851
PEO Actually Paid Compensation Amount $ 52,285,309 25,237,077 (2,674,822) 25,813,278 37,304,187
Adjustment To PEO Compensation, Footnote The dollar amounts reported in column (c) represent the amount of “compensation actually paid” (“CAP”) to the PEO computed in accordance with Item 402(v) of Regulation S-K. The dollar amounts do not reflect the actual amount of compensation earned by or paid to the PEO during the applicable year. In accordance with the requirements of Item 402(v) of Regulation S-K, the following adjustments were made to the PEO’s total compensation for each year to determine the CAP:

20252024
2023
2022
2021
Total Compensation from SCT$11,278,569$6,369,165$14,296,476$34,070,592$45,998,851
Less Reported Value of Equity Awards from SCT$(8,500,000)$(3,300,000)$(12,497,891)$(32,437,510)$(44,406,749)
Subtotal$2,778,569$3,069,165$1,798,585$1,633,082$1,592,102
Year-end fair value of any equity awards granted in applicable year that are outstanding and unvested as of the end of the year$10,830,663$7,425,000$16,247,259$27,710,914$20,804,877
The amount of change as of the end of the applicable year (from the end of the prior fiscal year) in fair value of any awards granted in prior years that are outstanding and unvested as of the end of the applicable year$13,493,655$17,121,231$(12,858,959)$(1,347,517)$8,950,439
For awards granted in prior years that vest in the applicable year, the amount equal to the change as of the vesting date (from the end of the prior fiscal year) in fair value$25,182,422$(2,378,320)$(7,861,706)$(2,183,201)$5,956,769
Net Adjustment to Subtotal$49,506,740$22,167,912$(4,473,407)$24,180,196$35,712,085
Compensation Actually Paid $52,285,309$25,237,077$(2,674,822)$25,813,278$37,304,187
        
Non-PEO NEO Average Total Compensation Amount $ 3,567,181 2,715,002 4,760,449 7,327,470 10,891,546
Non-PEO NEO Average Compensation Actually Paid Amount $ 11,082,021 7,114,604 1,769,823 5,661,779 10,053,244
Adjustment to Non-PEO NEO Compensation Footnote The dollar amounts reported in column (e) represent the average amount of CAP to the non-PEO NEOs as a group computed in accordance with Item 402(v) of Regulation S-K. The dollar amounts do not reflect the actual amount of compensation earned by or paid to the Non-PEO NEOs during the applicable year. In accordance with the requirements of Item 402(v) of Regulation S-K, the following adjustments were made to average total compensation for the Non-PEO NEOs for each year to determine the CAP:

20252024
2023
2022
2021
Average Total Compensation from SCT$3,567,181$2,715,002$4,760,449$7,327,470$10,891,546
Less Average Reported Value of Equity Awards from SCT$(2,330,000)$(1,350,000)$(3,786,785)$(6,383,827)$(9,913,214)
Subtotal$1,237,181$1,365,002$973,664$943,643$978,332
Year-end fair value of any equity awards granted in applicable year that are outstanding and unvested as of the end of the year$2,895,666$2,913,083$4,110,320$5,881,206$4,532,610
For awards granted and vested in the applicable year, the fair value at the vesting date$80,699————

20252024
2023
2022
2021
The amount of change as of the end of the applicable year (from the end of the prior fiscal year) in fair value of any awards granted in prior years that are outstanding and unvested as of the end of the applicable year$2,469,428$3,094,951$(1,755,990)$(551,977)$2,876,585
For awards granted in prior years that vest in the applicable year, the amount equal to the change as of the vesting date (from the end of the prior fiscal year) in fair value$4,399,048$(258,432)$(1,558,171)$(611,093)$1,665,717
Total Net Adjustment to Subtotal$9,844,841$5,749,602$796,159$4,718,136$9,074,912
Compensation Actually Paid$11,082,021$7,114,604$1,769,823$5,661,779$10,053,244
        
Compensation Actually Paid vs. Total Shareholder Return
5804
        
Compensation Actually Paid vs. Net Income
5806
        
Compensation Actually Paid vs. Company Selected Measure
5808
        
Total Shareholder Return Vs Peer Group
5804
        
Tabular List, Table Adjusted EBITDA
•Adjusted Gross Profit
•Revenue
Health Plan Membership
•CMS Star Ratings
        
Total Shareholder Return Amount $ 114.10 64.99 49.74 67.94 81.22
Peer Group Total Shareholder Return Amount 100.74 82.17 82.87 77.79 97.76
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest $ (1,000,000.00) $ (128,070,000.00) $ (148,170,000) $ (149,600,000) $ (195,300,000)
Company Selected Measure Amount 109,900,000 1,340,000 (35,300,000) (26,700,000) (33,100,000)
PEO Name Mr. Kao        
Additional 402(v) Disclosure
The following table and supporting graphics below set out information regarding the Company's last five completed fiscal years, in satisfaction of Item 402(v) of Regulation S-K, which requires disclosure regarding executive “Compensation Actually Paid” or “CAP” (as calculated in accordance with SEC rules) as compared to certain Company performance measures. You should refer to the “Compensation Discussion and Analysis” in this proxy statement for a complete description of how executive compensation relates to Company performance and how the Compensation Committee makes its decisions.
TSR is calculated by dividing (a) the sum of (i) the cumulative amount of dividends for the measurement period, assuming dividend reinvestment, and (ii) the difference between our share price at the end of each fiscal year shown and the beginning of the measurement period by (b) our share price at the beginning of the measurement period. Pursuant to rules of the SEC, the comparison assumes $100 was invested in our common stock at the closing price on March 26, 2021. Historic stock price performance is not necessarily indicative of future stock price performance.The dollar amounts reported represent the amount of net income reflected in the Company’s audited financial statements for the applicable year.
The performance measures listed below represent an unranked list of the “most important” performance measures that Alignment used to align CAP to the NEOs for 2025 and company performance. The role of each of these performance measures in our executive compensation program is discussed in the “Compensation Discussion and Analysis” section of this proxy statement. While these financial measures are the most important measures the company used to align CAP to the NEOs for 2025 and company performance, additional financial and other measures were also used to align pay and performance, as further described in the “Compensation Discussion and Analysis” section of this proxy statement.
As noted above, we have deemed adjusted EBITDA as the “most important” financial measure used to link our NEOs' compensation with performance and, as previously disclosed, it is being used as our company-selected measure in the pay-versus-performance table above. For more detail on these measures and why we believe that they are important in structuring our compensation programs and linking pay with performance, please see “Compensation Discussion and Analysis.”
Descriptions of the Information Presented in the Pay Versus Performance Table
The illustrations below compare CAP and the following measures:
•the Company’s cumulative TSR and the NASDAQ Healthcare Index’s cumulative TSR;
•the Company’s Net Income; and
•the Company’s Adjusted EBITDA.
        
Measure:: 1          
Pay vs Performance Disclosure          
Name Adjusted EBITDA        
Non-GAAP Measure Description Adjusted EBITDA is a non-GAAP financial measure that is presented as supplemental disclosure, that we define as net loss before interest expense, income taxes, depreciation and amortization expense, transaction-related expenses, acquisition expenses, certain litigation costs and settlements, gains or losses on ROU assets, equity-based compensation expense, and loss on extinguishment of debt. Adjusted EBITDA should not be considered in isolation of, or as an alternative to, measures prepared in accordance with U.S. generally accepted accounting principles (“GAAP”). There are a number of limitations related to the use of adjusted EBITDA in lieu of net loss, which is the most directly comparable financial measure calculated in accordance with GAAP. An explanation of our non-GAAP measures, how they are calculated and reconciliations to the most directly comparable GAAP financial measures can be found in the Appendix to this proxy statement.        
Measure:: 2          
Pay vs Performance Disclosure          
Name Adjusted Gross Profit        
Measure:: 3          
Pay vs Performance Disclosure          
Name Revenue        
Measure:: 4          
Pay vs Performance Disclosure          
Name Health Plan Membership        
Measure:: 5          
Pay vs Performance Disclosure          
Name CMS Star Ratings        
PEO          
Pay vs Performance Disclosure          
Adjustment To Compensation Amount, Subtotal $ 2,778,569 $ 3,069,165 $ 1,798,585 $ 1,633,082 $ 1,592,102
Adjustment To Compensation Amount, Net Adjustment To Subtotal 49,506,740 22,167,912 (4,473,407) 24,180,196 35,712,085
PEO | Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount (8,500,000) (3,300,000) (12,497,891) (32,437,510) (44,406,749)
PEO | Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount 10,830,663 7,425,000 16,247,259 27,710,914 20,804,877
PEO | Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount 13,493,655 17,121,231 (12,858,959) (1,347,517) 8,950,439
PEO | Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount 25,182,422 (2,378,320) (7,861,706) (2,183,201) 5,956,769
Non-PEO NEO          
Pay vs Performance Disclosure          
Adjustment To Compensation Amount, Subtotal 1,237,181 1,365,002 973,664 943,643 978,332
Adjustment To Compensation Amount, Net Adjustment To Subtotal 9,844,841 5,749,602 796,159 4,718,136 9,074,912
Non-PEO NEO | Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount (2,330,000) (1,350,000) (3,786,785) (6,383,827) (9,913,214)
Non-PEO NEO | Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount 2,895,666 2,913,083 4,110,320 5,881,206 4,532,610
Non-PEO NEO | Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount 2,469,428 3,094,951 (1,755,990) (551,977) 2,876,585
Non-PEO NEO | Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount 80,699 0 0 0 0
Non-PEO NEO | Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount $ 4,399,048 $ (258,432) $ (1,558,171) $ (611,093) $ 1,665,717